Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411071 | 0.94 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411133 | 0.91 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL2346512 | 0.91 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1410585 | 0.91 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411285 | 0.91 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411468 | 0.91 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411031 | 0.91 | PDE4B (0.46) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411659 | 0.90 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL2268044 | 0.90 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL1411271 | 0.89 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2295423-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257221-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.